CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Propanc Biopharma (PPCB) announced a strategic financing agreement with Hexstone Capital on October 15, 2025 providing up to $100 million of potential funding.
Key terms include issuance of 100 shares of Series C Convertible Preferred Stock for an initial $1.0 million (stated value $10,000 each) convertible at an initial price of $5.00 per share (a 280% premium to the recent $1.78 close). Propanc also issued 9,900 warrants to buy Preferred Stock at $9,999.99 each (up to $99 million), exercisable immediately for 12 months. The conversion includes variable alternative prices and a 4.99% beneficial ownership limitation. The agreement allows the company to call up to 500 warrants per month for $0.01 each (up to $5 million preferred stock per month), subject to equity and ownership limits. SEC Form 8-K contains full details.
Propanc Biopharma (PPCB) ha annunciato un accordo di finanziamento strategico con Hexstone Capital il 15 ottobre 2025 che prevede fino a 100 milioni di dollari di potenziale finanziamento.
I termini principali includono l'emissione di 100 azioni di Serie C di azioni privilegiate convertibili per un investimento iniziale di 1,0 milione di dollari (valore nominale 10.000 dollari ciascuna) convertibili a un prezzo iniziale di 5,00 dollari per azione (un premio del 280% rispetto alla chiusura recente di 1,78 dollari). Propanc ha anche emesso 9.900 warrant per comprare azioni privilegiate a 9.999,99 dollari ciascuna (fino a 99 milioni di dollari), esercitabili immediatamente per 12 mesi. La conversione prevede prezzi alternativi variabili e una limitazione di possessione beneficiaria al 4,99%. L'accordo permette all'azienda di richiamare fino a 500 warrant al mese per 0,01 dollari ciascuno (fino a 5 milioni di dollari di azioni privilegiate al mese), soggetto a limiti di capitale e proprietà. Il modulo SEC Form 8-K contiene i dettagli completi.
Propanc Biopharma (PPCB) anunció un acuerdo de financiación estratégico con Hexstone Capital el 15 de octubre de 2025 que proporciona hasta 100 millones de dólares de financiamiento potencial.
Los términos clave incluyen la emisión de 100 acciones de Serie C de acciones preferentes convertibles por una inversión inicial de 1,0 millón de dólares (valor nominal 10.000 dólares cada una) convertibles a un precio inicial de 5,00 dólares por acción (un premio del 280% respecto al cierre reciente de 1,78 dólares). Propanc también emitió 9.900 warrants para comprar acciones preferentes a 9.999,99 dólares cada una (hasta 99 millones de dólares), ejercibles de inmediato por 12 meses. La conversión incluye precios alternativos variables y una limitación de propiedad beneficiaria del 4,99%. El acuerdo permite a la compañía llamar hasta 500 warrants por mes por 0,01 dólar cada uno (hasta 5 millones de dólares de acciones preferentes por mes), sujeto a límites de equidad y propiedad. El Formulario SEC 8-K contiene todos los detalles.
Propanc Biopharma (PPCB)가 2025년 10월 15일 Hexstone Capital과의 전략적 자금조달 계약을 발표했고, 최대 1억 달러의 잠재적 자금을 제공합니다.
주요 조건에는 시리즈 C 변환 우선주 100주를 초기 투자 100만 달러로 발행하는 것이 포함되며(주당 명목가 1만 달러), 초기 가격은 주당 5.00달러로 전환 가능하며 최근 종가 1.78달러 대비 280% 프리미엄이 적용됩니다. Propanc는 또한 9,900개의 워런트를 발행하여 각 워런트당 9,999.99달러에 우선주를 매수할 수 있도록 했고(총액 최대 9,900만 달러), 즉시 행사 가능하며 12개월간 유효합니다. 전환은 가변 대체 가격과 4.99%의 유리한 소유 제한을 포함합니다. 이 계약은 회사가 월 500개의 워런트를 0.01달러에 매입할 수 있도록 허용하며(월 최대 5백만 달러의 우선주), 자본 및 소유 한도에 따라 달라집니다. SEC Form 8-K에 전체 세부 정보가 포함되어 있습니다.
Propanc Biopharma (PPCB) a annoncé le 15 octobre 2025 un accord de financement stratégique avec Hexstone Capital prévoyant jusqu'à 100 millions de dollars de financement potentiel.
Les termes clés comprennent l'émission de 100 actions de Série C des actions privilégiées convertibles pour un investissement initial de 1,0 million de dollars (valeur nominale 10 000 dollars chacun), convertibles à un prix initial de 5,00 dollars par action (une prime de 280% par rapport à la clôture récente de 1,78 dollars). Propanc a également émis 9 900 warrants pour acheter des actions privilégiées à 9 999,99 dollars chacun (jusqu'à 99 millions de dollars), immédiatement exerçables pendant 12 mois. La conversion comprend des prix alternatifs variables et une limite de possession bénéficiaire de 4,99%. L'accord permet à l'entreprise d'appeler jusqu'à 500 warrants par mois pour 0,01 dollar chacun (jusqu'à 5 millions de dollars d'actions privilégiées par mois), sous réserve des limites d'équité et de propriété. Le formulaire SEC 8-K contient tous les détails.
Propanc Biopharma (PPCB) kündigte am 15. Oktober 2025 eine strategische Finanzierungsvereinbarung mit Hexstone Capital an, die bis zu 100 Millionen USD potenzielle Finanzierung vorsieht.
Zu den wichtigsten Bedingungen gehört die Ausgabe von 100 Aktien der Serie C wandelbare Vorzugsaktien für eine anfängliche Investition von 1,0 Million USD (Nennwert 10.000 USD je Aktie), wandelbar zu einem anfänglichen Preis von 5,00 USD pro Aktie (ein Prämienniveau von 280% gegenüber dem jüngsten Schlusskurs von 1,78 USD). Propanc gab auch 9.900 Warrants aus, um Vorzugsaktien für je 9.999,99 USD zu kaufen (bis zu 99 Millionen USD), unmittelbar ausübbar für 12 Monate. Die Umwandlung umfasst variable alternative Preise und eine Beschränkung des beherrschenden Eigentums von 4,99%. Die Vereinbarung ermöglicht es dem Unternehmen, bis zu 500 Warrants pro Monat für je 0,01 USD zu erwerben (bis zu 5 Millionen USD Vorzugsaktien pro Monat), vorbehaltlich Kapital- und Eigentumsgrenzen. Die SEC Form 8-K enthält alle Details.
Propanc Biopharma (PPCB) أعلنت عن اتفاق تمويل استراتيجي مع Hexstone Capital في 15 أكتوبر 2025 يوفر تمويلاً يصل إلى 100 مليون دولار من التمويل المحتمل.
تشمل الشروط الأساسية إصدار 100 سهماً من سلسلة C من الأسهم الممتازة القابلة للتحويل باستثمار مبدئي قدره 1.0 مليون دولار (القيمة الاسمية 10,000 دولار لكل سهم) قابلة للتحويل بسعر ابتدائي قدره 5.00 دولار للسهم (علاوة بنسبة 280% عن الإغلاق الأخير عند 1.78 دولار). كما أصدرت Propanc 9,900 Warrants لشراء أسهم ممتازة بسعر 9,999.99 دولار لكل واحد (حتى 99 مليون دولار)، قابلة للإضراب فوراً لمدة 12 شهراً. يتضمن التحويل أسعاراً بديلة متغيرة وقيود ملكية مستفيدة بنسبة 4.99%. تسمح الاتفاقية للشركة باستدعاء حتى 500 warrants شهرياً مقابل 0.01 دولار لكل واحد (حتى 5 ملايين دولار من الأسهم الممتازة شهرياً)، رهناً بحدود الملكية والحقوق. يحتوي نموذج SEC Form 8-K على التفاصيل الكاملة.
Propanc Biopharma (PPCB) 于 2025 年 10 月 15 日 宣布与 Hexstone Capital 的战略融资协议，提供最高 1 亿美元 的潜在资金。
主要条款包括发行 100 股 Series C 可转换优先股，初始投资额为 100 万美元（面值每股 10,000 美元），可按初始价格 5.00 美元/股 转换，相对于最近收盘价 1.78 美元，存在 280% 的溢价。Propanc 还发行 9,900 份认股权证，以每份 9,999.99 美元 购买优先股（总额最高 9900 万美元），可立即行使，有效期为 12 个月。转换包括可变的替代价格和 4.99% 的受益所有权限制。协议允许公司每月最多调用 500 份认股权证，每份 0.01 美元（每月最多 500 万美元的优先股），须受股本与所有权限制。SEC Form 8-K 含有完整细节。
- Potential funding capacity of $100 million
- Initial committed investment of $1.0 million
- Warrants provide up to $99 million immediate raise opportunity
- Initial conversion price set at $5.00 per share (280% premium)
- Conversion and warrant exercises may cause significant dilution to common shareholders
- Beneficial ownership cap of 4.99% may constrain single-investor stake and transaction flexibility
- Monthly call provision could convert up to $5 million preferred per month, increasing near-term dilution risk
Initial Conversion Price of
MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to
Transaction Overview
Under the terms of the agreement, Propanc will issue 100 shares of newly designated Series C Convertible Preferred Stock, each with a par value of
The Preferred Stock is convertible into Common Stock at an initial conversion price of
Additionally, Propanc will issue 9,900 Warrants to Hexstone, each entitling the purchase of one share of Preferred Stock at
Further details can be found in the Company’s Form 8-K filed with the SEC and accessible at www.sec.gov.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. is developing a novel therapeutic approach aimed at preventing the recurrence and metastasis of solid tumors by leveraging the anti-cancer potential of pancreatic proenzymes. The Company’s lead product candidate targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.
The therapy is based on the concept that pancreatic enzymes, known to stimulate essential biological reactions in the body, may serve as a natural defense mechanism against cancer.
For more information, please visit www.propanc.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What financing did Propanc (PPCB) announce on October 15, 2025?
What are the conversion terms for Propanc's Series C preferred in the Hexstone deal (PPCB)?
How much immediate capital can Propanc raise from the Hexstone warrants (PPCB)?
When are the Hexstone warrants exercisable and for how long for Propanc (PPCB)?
What is the near-term dilution risk to Propanc (PPCB) shareholders from this transaction?
Where can investors find the full legal terms of the Propanc (PPCB) financing with Hexstone?
